The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppressionconnecting the dots.

The prostate gland is one of the only tissues in the human body that deliberately poisons its own energy supply. Every other cell burns citrate for fuel, as it is a core intermediate of the Krebs cycle, the engine of cellular respiration. However, normal prostate cells hoard citrate, refuse to oxidize it, and dump it into prostatic fluid at concentrations roughly a thousand times higher than blood plasma. This bizarre metabolic choice, according to Costello and Franklin, is the exact vulnerability that cancer exploits. The numbers here are significant. Blood plasma contains about 0.2 millimolar citrate. Normal peripheral zone prostate tissue, which is the outer region of the gland where most cancers arise, contains somewhere between 12,000 and 14,000 nanomoles per gram of wet weight. Most other tissues sit around 250 to 450 nanomoles per gram. The prostate isn't just slightly unusual; it operates in a different league entirely. The mechanism behind this is zinc. The prostate accumulates zinc at levels of roughly 3,000 to 4,500 nanomoles per gram, compared to 200 to 400 in most other tissues. That zinc floods into the mitochondria and inhibits an enzyme called m-aconitase, which would normally convert citrate into isocitrate as the first step of citrate oxidation. Blocked there, citrate pools up and gets exported for secretion. The Krebs cycle is deliberately truncated. Feeding that secretory machine requires a dedicated biochemical pathway. Costello and Franklin describe what they call the aspartate-glutamate-citrate pathway, or the AGC pathway, as the engine behind this production. To synthesize citrate, prostate cells need two inputs: acetyl-CoA, derived from glucose, and oxaloacetate. Instead of drawing oxaloacetate from the Krebs cycle as most cells do, prostate epithelial cells maintain a large internal pool of aspartate and use it as the source of oxaloacetate. The transporter EAAC1 pulls aspartate into the cells against a steep concentration gradient. Plasma aspartate runs about 0.03 micromoles per milliliter, while intracellular levels reach around 1.2 millimolar. Inside the mitochondria, the enzyme mitochondrial aspartate aminotransferase, working in concert with glutamate dehydrogenase, converts that aspartate into the oxaloacetate needed to make citrate. The energy cost is steep. A complete glucose oxidation yields 38 adenosine triphosphate, or ATP. The citrate-producing prostate cell, because it refuses to burn its own product, gets only about 14 ATP per glucose, sacrificing roughly 60 percent of the available energy. That is the price the tissue pays for its secretory function, defined by Costello and Franklin as the prostate's metabolic identity — the baseline from which cancer departs. When prostate cells turn malignant, the first thing they lose is zinc. Specifically, they lose the ability to accumulate it. ZIP1, the primary zinc uptake transporter in prostate cells, is downregulated in malignant glands. With zinc gone, mitochondrial aconitase is no longer inhibited, leading to citrate stopping its accumulation. Instead, citrate gets routed back into the Krebs cycle and oxidized. The cell flips from a specialized secretor into a conventional energy-maximizing machine. The bioenergetic payoff is immediate. Those approximately 24 ATP per glucose that the normal cell had sacrificed to maintain its secretory phenotype are suddenly available to the tumor. But that's only part of what the malignant cell gains. Citrate exported to the cytosol gets cleaved by ATP citrate lyase into acetyl-CoA, and that cytosolic acetyl-CoA feeds de novo lipid synthesis and cholesterol production, providing the membrane materials that a rapidly dividing cell needs. Costello and Franklin are direct about what this means: without this metabolic transformation, they argue, a neoplastic prostate cell will not progress to full malignancy. The metabolic switch is not just a side effect of cancer; it is a driver. The case for ZIP1 as a tumor suppressor gene is built on converging evidence. Costello and Franklin compiled 17 published reports measuring zinc in prostate tissue. The pooled result shows that normal prostate averages 755 units of zinc, while prostate cancer averages 276, marking a 68 percent decrease with a p-value below 0.001. Individual sample data indicate that cancer zinc levels are down roughly 85 percent relative to normal, showing no overlap between cancer values and the high-zinc normal or benign tissue. Both ZIP1 expression and ZIP1 protein are downregulated in malignant glands in situ, and the loss of the transporter correlates directly with the cellular zinc depletion. Because ZIP1 expression reappears in cultured prostate cell lines, the authors reason that the silencing isn't due to gene deletion; it's epigenetic. This matters enormously for treatment because epigenetic silencing can, in principle, be reversed. The consequences of zinc depletion extend beyond the citrate switch. Zinc accumulation in normal cells inhibits cell growth and proliferation, induces apoptosis through cytochrome c release and caspase activation, suppresses invasive capabilities, and inhibits nuclear factor kappa-light-chain-enhancer of activated B cells signaling, a pathway that promotes cell survival. Lose the zinc, and all of those tumor-suppressive effects go with it. The single molecular event of ZIP1 silencing cascades into a simultaneous metabolic and anti-tumor collapse. This biochemistry has a direct clinical translation, particularly through imaging. Because normal peripheral zone tissue is saturated with citrate while malignant tissue is not, the citrate signal becomes a diagnostic marker that can be read in a living patient. Proton magnetic resonance spectroscopy imaging, known as one H MRSI, a technique that measures chemical concentrations in tissue using magnetic resonance imaging, can map that depletion in situ. Kurhanewicz and colleagues produced what Costello and Franklin describe as a strikingly consistent result across early clinical studies: peripheral zone citrate is reduced in prostate cancer compared to normal or benign tissue, and none of the cancer patients retained the high citrate levels characteristic of healthy glands. MRSI also detects rising choline and creatine in malignant loci, so the ratio of citrate to the choline-plus-creatine signal becomes a diagnostic signature for peripheral zone malignancy. The payoff isn't just detection; combined magnetic resonance imaging and MRSI maps enable MRSI-guided radiotherapy, allowing clinicians to concentrate treatment on metabolically defined tumor tissue rather than relying on anatomical estimates. This brings us to the question that the whole argument has been building toward: if zinc loss drives the transformation, can restoring zinc reverse or prevent it? Costello and Franklin are cautiously specific here, and their caution is itself informative. Genetic restoration of ZIP1 is conceptually attractive but not yet practical. Pharmacological delivery of zinc using ionophores like sodium pyrithione could ferry zinc across cell membranes, but the lack of cell-type specificity raises toxicity concerns. Targeting m-aconitase directly with inhibitors like fluorocitrate runs into the same problem — the effect isn't confined to prostate cells. Dietary zinc supplementation is the most accessible option. They note that moderate supplementation in elderly males would help maintain normal plasma zinc levels and does not impose additional risk, though they are careful not to overstate what dietary zinc alone can achieve. Two hard constraints bound any zinc-based strategy. First, there must be sufficient zinc available in the tissue interstitium for cells to import. Second, the cells must still express a functional zinc uptake mechanism — specifically, ZIP1 must still be accessible. If ZIP1 is epigenetically silenced, zinc supplementation alone does nothing; there is substrate but no transporter. The authors emphasize timing: intervening at the neoplastic or premalignant stage, before ZIP1 is fully silenced, is likely the window where zinc restoration could suppress malignancy. Later, the door may already be closed. The deeper argument that Costello and Franklin are making is not just about prostate cancer. It's about how we think about cancer metabolism in general. The field has long treated altered metabolism as a downstream consequence of oncogene activation — cells become malignant and then happen to change how they metabolize. The prostate story inverts that framing. Here, a specific metabolic identity — the citrate-secreting, zinc-accumulating, energetically costly normal cell — is actively maintained by a tumor suppressor gene. When that gene is silenced, the metabolic transformation doesn't follow malignancy; it enables it. The zinc-citrate axis in prostate cells is a case where connecting the molecular dots leads somewhere genuinely actionable: a measurable biomarker visible on a clinical scan, a quantifiable tissue signature across dozens of studies, and a mechanistic target with at least a plausible therapeutic path. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.